Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Olalekan O. Oluwole, Sally W. Wade, Nathaniel J Smith, Tomas Spousta, Jenny J. Kim, Yan Zheng, Timothy Best, Markqayne Ray, Lori A. Leslie

Blood (2024) 144 (Supplement 1): 7607.

https://doi.org/10.1182/blood-2024-206879

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin

Blood (2024) 144 (Supplement 1): 609.

https://doi.org/10.1182/blood-2024-207976

Published: 2024

Journal Articles

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Blood (2024) 144 (Supplement 1): 7159.

https://doi.org/10.1182/blood-2024-209570

Published: 2024

Journal Articles

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts

Sandeep Raj, Jin Xie, Teng Fei, Qinghua Song, Jenny J. Kim, Christina To, Marcel R.M. van den Brink, Miguel-Angel Perales, Mike Mattie, Roni Shouval

Blood (2023) 142 (Supplement 1): 224.

https://doi.org/10.1182/blood-2023-173798

Published: 2023

Journal Articles

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Dimitra Karagkouni, Xanthi Lida Katopodi, Giulia Cheloni, Yuling Ma, Brodie Miles, Gayatri Tiwari, Jenny J. Kim, Mike Mattie, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2023) 142 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2023-190377

Published: 2023

Journal Articles

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Mike Mattie, Melanie Grosso, Aurelie Auguste, Denis Arnaud, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Jenny Nater, Rhine R. Shen, Jerome Galon

Blood (2023) 142 (Supplement 1): 226.

https://doi.org/10.1182/blood-2023-187574

Published: 2023

Journal Articles

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Blood (2023) 142 (Supplement 1): 103.

https://doi.org/10.1182/blood-2023-175034

Published: 2023

Journal Articles

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Clare Spooner, Jenny J. Kim, Harry Miao, Allen Xiaodong Xue, Yan Zheng, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2023-174288

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Carli M. Stewart, Michelle J. Cox, Reona Leo Sakemura, Ekene J. Ogbodo, Ismail Can, Claudia Manriquez-Roman, Kun Yun, Olivia Sirpilla, James H. Girsch, Truc Huynh, Elizabeth L. Siegler, Jenny J Kim, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 4536–4537.

https://doi.org/10.1182/blood-2022-160219

Published: 2022

Journal Articles

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 901.

https://doi.org/10.1182/blood-2021-148591

Published: 2021

Journal Articles

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Qinghua Song, Tao Hu, Sattva S. Neelapu, Frederick L. Locke, Caron Jacobson, David B. Miklos, Olalekan O. Oluwole, Marie José Kersten, Max Topp, Jenny J. Kim, Kanwarjit Singh, Jorge Andrade, Lei Huang, Allen Xue, Marco Schupp, Myrna Nahas, Rhine R. Shen, Adrian Bot

Blood (2021) 138 (Supplement 1): 2833.

https://doi.org/10.1182/blood-2021-148580

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136136

Published: 2020

Journal Articles

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-134362

Published: 2020

Journal Articles

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke

Blood (2020) 135 (23): 2106–2109.

https://doi.org/10.1182/blood.2019004162

Published: 2020

Includes: Supplemental data

Journal Articles

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Sattva S Neelapu, MD, John M. Rossi, MS, Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Patrick M Reagan, MD, Scott J Rodig, MD PhD, Lazaros J. Lekakis, MD, Ian W. Flinn, MD PhD, Lianqing Zheng, PhD, Francesca Milletti, PhD, Edmund Chang, PhD, Allen Xue, PhD, Vicki Plaks, PhD, Jenny J. Kim, MD MS, Adrian Bot, MD PhD

Blood (2019) 134 (Supplement_1): 203.

https://doi.org/10.1182/blood-2019-126218

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

NARROW

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only